H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating on uniQure (QURE) with a $70 price target after the company announced positive data from the U.S. and European Phase 1/2 clinical trials evaluating a one-time dose of AMT-130 in patients with early manifest Huntington’s disease. AMT-130 showed a robust, statistically significant and dose-dependent slowing of the rate of disease progression compared to an external natural history cohort, and also appears to substantially slow neurological decline relative to baseline, the analyst tells investors in a research note. The firm believes the data establish AMT-130 as a leading candidate in Huntington’s, and support a biologics license application filing in Q1 and 2026 with potential accelerated approval. uniQure remains a top pick at H.C. Wainwright.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- Leerink says uniQure stock could trade up 100% on HD study data
- PTC shares to see pressure on ‘compelling’ uniQure data, says Citi
- PTC Therapeutics down 3% after uniQure Huntington’s disease data
- Morning Movers: uniQure skyrockets after AMT-130 trial meets primary endpoint
- uniQure soars 167% to $36.50 in pre-market after AMT-130 study met endpoint